Heart rate-lowering efficacy and respiratory safety of ivabradine in patients with obstructive airway disease: a randomized, double-blind, placebo-controlled, crossover study
American Journal of Cardiovascular Drugs,  Clinical Article

Majewski S et al. – This study demonstrated that selective heart rate (HR) reduction with ivabradine is effective in patients with asthma and chronic obstructive pulmonary disease (COPD), with no alteration in respiratory function or symptoms over the duration of the study. Ivabradine offers an interesting alternative, as an HR–lowering agent, in patients with respiratory disease and contraindications to β–blockers.

Methods
  • This was a randomized, single–center, double–blind, placebo–controlled, crossover trial.
  • Enrolment began in May 2009, and the last patient completed the study in January 2011.
  • The study was conducted in an ambulatory setting.
  • A total of 40 patients completed the study (20 asthmatic patients and 20 COPD patients).
  • Inclusion criteria were: documented diagnosis of asthma or COPD according to international guidelines, age 18–75 years, and mean HR on Holter ECG recording of ≥60beats/min.
  • Exclusion criteria included disease exacerbation in a previous month or inability to understand instructions on the study procedures.
  • All patients received ivabradine 7.5mg twice daily for 5 days and placebo twice daily for 5 days in a crossover manner, in one of the two arms of the study, with at least 2 days of washout between treatments.
  • The main outcome measures included the difference in HR between ivabradine and placebo treatment and change in HR in comparison with baseline.
  • Other evaluated outcomes were differences in the peak expiratory flow rate (PEFR), the daily symptom score, rescue medication consumption, and AEs.

Results
  • Ivabradine produced significantly lower mean HR than placebo in both groups of patients: asthma 67.4±8.38 versus 82.85±11.19beats/min (p<0.001) and COPD 69.75±8.9 versus 81.05±9.75beats/min (p<0.001).
  • Similar results were observed for the minimal HR as well as for the maximal noted HR.
  • In comparision with baseline, ivabradine significantly reduced HR in both groups of studied patients (all p<0.05), whereas placebo did not have such an effect.
  • No significant difference, in either the asthma or the COPD group, was found between ivabradine and placebo in morning and evening peak expiratory flow rate, peak expiratory flow diurnal variability, daily symptom scores, and rescue medication usage (all p>0.05).
  • Both treatments were well tolerated.
  • The incidence of AEs was low and generally similar in both periods of treatment, except for visual symptoms during treatment with ivabradine, which was reported by 5% of the patients.

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Pharmacy

See All >> Messages include industry-sponsored communications and special communications from MDLinx

<

Most Popular Pharmacy Articles

1 Commonly prescribed drug for lower back pain not effective University of Rochester Medical Center, December 12, 2014

2 New drug could make vaccines more effective in the elderly University of Oxford News, November 14, 2014

3 Widely used osteoporosis drugs may prevent breast, lung and colon cancers The Mount Sinai Hospital, December 3, 2014

4 Omega-3 fatty acids and other FFA4 agonists inhibit growth factor signaling in human prostate cancer cells Journal of Pharmacology and Experimental Therapeutics, December 10, 2014    Clinical Article

5 Factors affecting time to maintenance dose in patients initiating warfarin Pharmacoepidemiology and Drug Safety, December 12, 2014    Clinical Article

6 New use for an old drug could impact cirrhosis patients Baylor Health Care System, November 6, 2014

7 Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: The SOLO II Noninferiority Study Clinical Infectious Diseases, December 1, 2014    Clinical Article

8 Effectiveness of azithromycin in aspiration pneumonia: A prospective observational study Full Text BMC Infectious Diseases, December 12, 2014    Free full text    Clinical Article

9 Proton pump inhibitor treatment is associated with the severity of liver disease and increased mortality in patients with cirrhosis Alimentary Pharmacology and Therapeutics, December 24, 2014    Clinical Article

10 Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial The Lancet Oncology, December 24, 2014    Clinical Article

11 Statins reverse learning disabilities caused by genetic disorder UCLA Health System, November 18, 2014

12 Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease Full Text Clinical and Experimental Gastroenterology, December 15, 2014    Free full text    Review Article

13 Efficacy of atomoxetine versus midodrine for the treatment of orthostatic hypotension in autonomic failure Hypertension, November 24, 2014    Clinical Article

14 Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia Full Text JAMA, June 4, 2014    Free full text    Evidence Based Medicine    Clinical Article

15 UCLA researchers find that drug used for another disease slows progression of Parkinson's UCLA Health System, October 10, 2014

16 Treatment of gram - positive infections in critically ill patients Full Text BMC Infectious Diseases, December 12, 2014    Free full text    Clinical Article

17 A meta-analysis of randomized controlled trials of the risk of bleeding with apixaban versus vitamin K antagonists The American Journal of Cardiology, December 5, 2014    Evidence Based Medicine    Review Article

18 Interactions between herbs and antidiabetics: an overview of the mechanisms, evidence, importance, and management Full Text Archives of Pharmacal Research, December 9, 2014    Free full text    Review Article

19 Toughest breast cancer may have met its match Johns Hopkins Medicine, December 11, 2014

20 High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection Clinical Gastroenterology and Hepatology , November 24, 2014    Clinical Article

Indexed Journals in Pharmacy: Expert Opinion in Pharmacotherapy, Formulary, U.S.Pharmacistmore

Make smarter career moves with less time.

Sign up for our free job placement service today and have a dedicated career consultant help locate the right physician job for you!
Click Here for more information.

Get Started Now!

Free-of-charge, no obligation.

Terms and Conditions For M3 Career Consult

By registering with the M3 Career Consult service you authorize M3 USA Corporation to represent you in your job search. The following is a summary of the terms of our service and our mutual obligations to help you find a job:

  • You designate M3 to act as your agent and represent you in your job search;
  • You will not pay us for this service
  • You will advise us of any companies or positions to which you apply or have applied;
  • You will advise us if you believe you are not capable of performing a position for which we submit you, or for which you interview;
  • You will keep all information we provide you about companies or positions strictly confidential;
  • You will promptly provide us with information we request of you;
  • You will make yourself reasonably available for phone, video and in-person conversations and interviews;
  • You will be truthful in all of your communications with us; and
  • You will advise us if anything above changes.
 

The Top Read Articles of 2014 are Now Available

Scouring thousands of peer-reviewed journals and popular press, Our Editors just released the Top Read Articles of the Year. See the Top Read List